Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT

Hematopoietic stem cell transplantation (HSCT) has improved over the last few decades. However, viral infections are often refractory to pharmacologic treatment and require alternative treatment strategies such as immunotherapy. Adenovirus (AdV) is th predominant disease-causing pathogen in pediatri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Feucht, Judith (VerfasserIn) , Greil, Johann (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 23, 2015
In: Blood
Year: 2015, Jahrgang: 125, Heft: 12, Pages: 1986-1994
ISSN:1528-0020
DOI:10.1182/blood-2014-06-573725
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1182/blood-2014-06-573725
Verlag, kostenfrei, Volltext: http://www.bloodjournal.org/content/125/12/1986
Volltext
Verfasserangaben:Judith Feucht, Kathrin Opherk, Peter Lang, Simone Kayser, Lena Hartl, Wolfgang Bethge, Susanne Matthes-Martin, Peter Bader, Michael H. Albert, Britta Maecker-Kolhoff, Johann Greil, Hermann Einsele, Paul-Gerhardt Schlegel, Friedhelm R. Schuster, Bernhard Kremens, Claudia Rossig, Bernd Gruhn, Rupert Handgretinger, and Tobias Feuchtinger

MARC

LEADER 00000caa a2200000 c 4500
001 1562767305
003 DE-627
005 20230427122041.0
007 cr uuu---uuuuu
008 170828s2015 xx |||||o 00| ||eng c
024 7 |a 10.1182/blood-2014-06-573725  |2 doi 
035 |a (DE-627)1562767305 
035 |a (DE-576)492767300 
035 |a (DE-599)BSZ492767300 
035 |a (OCoLC)1340978909 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Feucht, Judith  |d 1984-  |e VerfasserIn  |0 (DE-588)1014089220  |0 (DE-627)66573753X  |0 (DE-576)348287658  |4 aut 
245 1 0 |a Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT  |c Judith Feucht, Kathrin Opherk, Peter Lang, Simone Kayser, Lena Hartl, Wolfgang Bethge, Susanne Matthes-Martin, Peter Bader, Michael H. Albert, Britta Maecker-Kolhoff, Johann Greil, Hermann Einsele, Paul-Gerhardt Schlegel, Friedhelm R. Schuster, Bernhard Kremens, Claudia Rossig, Bernd Gruhn, Rupert Handgretinger, and Tobias Feuchtinger 
264 1 |c January 23, 2015 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.08.2017 
520 |a Hematopoietic stem cell transplantation (HSCT) has improved over the last few decades. However, viral infections are often refractory to pharmacologic treatment and require alternative treatment strategies such as immunotherapy. Adenovirus (AdV) is th predominant disease-causing pathogen in pediatric HSCT. In a clinical trial, we analyzed safety and efficacy of ex vivo adoptive T-cell transfer (ACT) with hexon-specific T cells, predominantly of the T-helper cell 1 (Th1) phenotype, in 30 patients with AdV disease or viremia. ACT was feasible with no acute toxicities or significant onset of graft-versus-host disease. ACT led to in vivo antiviral immunity for up to 6 months with viral control, resulting in complete clearance of viremia in 86% of patients with antigen-specific T-cell responses. After ACT and a follow-up of 6 months, overall survival was markedly increased in responders (mean, 122 days; 15 survivors) compared with nonresponders who all died shortly after ACT (mean, 24 days; no survivors). AdV-related mortality was 100% in nonresponders compared with 9.5% in responders (≥1 log reduction of DNA copies per milliliter after ACT). In summary, ex vivo ACT of AdV-specific Th1 cells was well tolerated and led to successful and sustained restoration of T-cell immunity correlated with virologic response and protection from virus-related mortality. This cellular immunotherapy is a short-term available and broadly applicable treatment. The study is registered at European Union Clinical Trials Register as 2005-001092-35. 
700 1 |a Greil, Johann  |e VerfasserIn  |0 (DE-588)1078331979  |0 (DE-627)838332455  |0 (DE-576)450711498  |4 aut 
773 0 8 |i Enthalten in  |t Blood  |d Washington, DC : American Society of Hematology, 1946  |g 125(2015), 12, Seite 1986-1994  |h Online-Ressource  |w (DE-627)266886647  |w (DE-600)1468538-3  |w (DE-576)075961938  |x 1528-0020  |7 nnas  |a Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT 
773 1 8 |g volume:125  |g year:2015  |g number:12  |g pages:1986-1994  |g extent:9  |a Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT 
856 4 0 |u http://dx.doi.org/10.1182/blood-2014-06-573725  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://www.bloodjournal.org/content/125/12/1986  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20170828 
993 |a Article 
994 |a 2015 
998 |g 1078331979  |a Greil, Johann  |m 1078331979:Greil, Johann  |d 910000  |d 910500  |e 910000PG1078331979  |e 910500PG1078331979  |k 0/910000/  |k 1/910000/910500/  |p 11 
999 |a KXP-PPN1562767305  |e 2978619104 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 28.08.2017"],"recId":"1562767305","language":["eng"],"title":[{"title_sort":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT"}],"person":[{"family":"Feucht","given":"Judith","roleDisplay":"VerfasserIn","display":"Feucht, Judith","role":"aut"},{"given":"Johann","family":"Greil","role":"aut","roleDisplay":"VerfasserIn","display":"Greil, Johann"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"pubHistory":["1.1946 -"],"part":{"text":"125(2015), 12, Seite 1986-1994","volume":"125","extent":"9","year":"2015","pages":"1986-1994","issue":"12"},"titleAlt":[{"title":"Blood online"}],"disp":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCTBlood","note":["Gesehen am 21.04.2023"],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Society of Hematology"}],"language":["eng"],"recId":"266886647","title":[{"title":"Blood","subtitle":"journal of the American Society of Hematology","title_sort":"Blood"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1946-","dateIssuedKey":"1946","publisher":"American Society of Hematology ; Saunders ; HighWire Press","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif."}],"id":{"issn":["1528-0020"],"eki":["266886647"],"zdb":["1468538-3"]}}],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"January 23, 2015"}],"id":{"eki":["1562767305"],"doi":["10.1182/blood-2014-06-573725"]},"name":{"displayForm":["Judith Feucht, Kathrin Opherk, Peter Lang, Simone Kayser, Lena Hartl, Wolfgang Bethge, Susanne Matthes-Martin, Peter Bader, Michael H. Albert, Britta Maecker-Kolhoff, Johann Greil, Hermann Einsele, Paul-Gerhardt Schlegel, Friedhelm R. Schuster, Bernhard Kremens, Claudia Rossig, Bernd Gruhn, Rupert Handgretinger, and Tobias Feuchtinger"]}} 
SRT |a FEUCHTJUDIADOPTIVETC2320